Beese Fulmer Investment Management Inc. Sells 7,899 Shares of Edwards Lifesciences Co. (NYSE:EW)

Beese Fulmer Investment Management Inc. decreased its position in shares of Edwards Lifesciences Co. (NYSE:EW) by 5.3% in the 3rd quarter, according to its most recent 13F filing with the SEC. The firm owned 140,025 shares of the medical research company’s stock after selling 7,899 shares during the quarter. Beese Fulmer Investment Management Inc.’s holdings in Edwards Lifesciences were worth $9,240,000 at the end of the most recent quarter.

Several other large investors also recently added to or reduced their stakes in EW. Global Assets Advisory LLC purchased a new position in shares of Edwards Lifesciences in the first quarter worth about $3,053,000. Riverview Trust Co bought a new stake in Edwards Lifesciences during the first quarter valued at $34,000. Brookstone Capital Management boosted its stake in Edwards Lifesciences by 3.2% during the first quarter. Brookstone Capital Management now owns 12,275 shares of the medical research company’s stock valued at $1,173,000 after buying an additional 383 shares during the period. Chesley Taft & Associates LLC grew its position in Edwards Lifesciences by 0.6% during the first quarter. Chesley Taft & Associates LLC now owns 30,551 shares of the medical research company’s stock worth $2,919,000 after buying an additional 184 shares in the last quarter. Finally, 180 Wealth Advisors LLC increased its stake in Edwards Lifesciences by 1.8% in the 1st quarter. 180 Wealth Advisors LLC now owns 10,124 shares of the medical research company’s stock worth $967,000 after acquiring an additional 183 shares during the last quarter. Hedge funds and other institutional investors own 79.46% of the company’s stock.

Edwards Lifesciences Stock Up 2.0 %

EW stock opened at $70.63 on Thursday. The company has a quick ratio of 2.87, a current ratio of 3.71 and a debt-to-equity ratio of 0.08. The business has a 50 day moving average of $68.04 and a 200 day moving average of $78.71. Edwards Lifesciences Co. has a twelve month low of $58.93 and a twelve month high of $96.12. The firm has a market cap of $42.56 billion, a PE ratio of 30.44, a price-to-earnings-growth ratio of 2.83 and a beta of 1.13.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings results on Wednesday, July 24th. The medical research company reported $0.70 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.69 by $0.01. The company had revenue of $1.63 billion for the quarter, compared to analysts’ expectations of $1.65 billion. Edwards Lifesciences had a net margin of 24.55% and a return on equity of 22.35%. Edwards Lifesciences’s revenue was up 6.7% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.66 EPS. On average, research analysts forecast that Edwards Lifesciences Co. will post 2.71 EPS for the current fiscal year.

Insider Activity at Edwards Lifesciences

In other Edwards Lifesciences news, VP Daveen Chopra sold 1,250 shares of the business’s stock in a transaction dated Tuesday, August 20th. The stock was sold at an average price of $69.95, for a total value of $87,437.50. Following the completion of the transaction, the vice president now owns 29,333 shares of the company’s stock, valued at approximately $2,051,843.35. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other news, VP Donald E. Bobo, Jr. sold 5,000 shares of the business’s stock in a transaction on Wednesday, September 11th. The shares were sold at an average price of $66.77, for a total transaction of $333,850.00. Following the completion of the sale, the vice president now owns 46,936 shares of the company’s stock, valued at $3,133,916.72. The trade was a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, VP Daveen Chopra sold 1,250 shares of Edwards Lifesciences stock in a transaction on Tuesday, August 20th. The shares were sold at an average price of $69.95, for a total value of $87,437.50. Following the transaction, the vice president now owns 29,333 shares in the company, valued at $2,051,843.35. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 16,250 shares of company stock valued at $1,099,238 over the last 90 days. Corporate insiders own 1.29% of the company’s stock.

Analyst Ratings Changes

Several brokerages have issued reports on EW. Oppenheimer reiterated an “outperform” rating and set a $90.00 target price on shares of Edwards Lifesciences in a research report on Thursday, September 12th. Stifel Nicolaus lowered their price target on Edwards Lifesciences from $85.00 to $70.00 and set a “hold” rating on the stock in a research report on Thursday, July 25th. TD Cowen cut Edwards Lifesciences from a “buy” rating to a “hold” rating and cut their price objective for the stock from $100.00 to $70.00 in a report on Thursday, July 25th. Robert W. Baird cut Edwards Lifesciences from an “outperform” rating to a “neutral” rating and decreased their price objective for the company from $102.00 to $70.00 in a report on Thursday, July 25th. Finally, Barclays reduced their price target on shares of Edwards Lifesciences from $90.00 to $80.00 and set an “overweight” rating on the stock in a research report on Monday, September 9th. Fifteen analysts have rated the stock with a hold rating, ten have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $75.81.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.